Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 2/2009

01-02-2009 | Editorial

Controlling Cervical Cancer

Authors: Maurizio Bonati, Prof. Silvio Garattini

Published in: PharmacoEconomics | Issue 2/2009

Login to get access

Excerpt

Every year, about half a million women worldwide are diagnosed with cervical cancer (the second most common cancer in women) and more than 250 000 die from the disease. It is the leading cancer in women in half the countries in the world and mostly affects relatively young, poor women.[1] About 80% of cervical cancer deaths are in developing countries, and about 60% of cases are in Latin America and the Asia-Pacific region.[2] In developing countries, the incidence is rising with population growth and aging, and preventive programmes have largely failed because they are too expensive and complicated. …
Literature
1.
Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 Suppl. 10: K1–16CrossRef
2.
Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine 2008; 26 Suppl. 10: K76–86CrossRef
3.
McCrory DC, Matchar DB, Bastian L, et al. Evaluation of cervical cytology. Evid Rep Technol Assess (Summ) 1999; 5: 1–64.
4.
Wright TC, Bosch FX, Franco EL, et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer. Conclusions from a 2006 workshop of international experts. Vaccine 2006; 24 Suppl. 3: S251–61CrossRef
5.
zur Hausen H, Meinhof W, Scheiber W, et al. Attempts to detect virus-specific DNA in human tumors: I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int J Cancer 1974; 13 (5): 650–6PubMedCrossRef
6.
Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 Suppl. 3; S3/11–25
7.
Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123–37PubMedCrossRef
8.
Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003–2005. Ann Intern Med 2008; 148: 493–500PubMed
9.
Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 2008; 26 (49): 6258–65PubMedCrossRef
10.
Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination: implications for second generation vaccines. Vaccine 2008; 26 Suppl. 10: K62–7CrossRef
11.
Gravitt PE, Coutlée F, Iftner T, et al. New technologies in cervical cancer screening. Vaccine 2008; 26 Suppl. 10: K42–52CrossRef
12.
Cuzick J, Arbyn M, Sankaranarayanan T, et al. Overview of human papilloma virus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26 Suppl. 10: K29–41CrossRef
13.
Kitchener HC, Castle PE, Cox JT. Achievements and limitation of cervical cytology screening. In: Bosch FX, editor. HPV vaccines and screening in the prevention of cervical cancer. Vaccine 2006; 24 Suppl. 3: S3–63
14.
15.
Kim JJ. Human papillomavirus vaccination in the UK. BMJ 2008; 337: a842
16.
Haug CJ. Human papillomavirus vaccination: reasons for caution. N Engl J Med 2008; 359 (8): 861–2PubMedCrossRef
17.
Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13: 631–9PubMedCrossRef
18.
Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28: 88–100PubMedCrossRef
19.
Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3: e138
20.
Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28–41PubMedCrossRef
21.
Newall AT, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7: 289–96PubMedCrossRef
22.
Barnabas RV, Kulasingam SL. Economic evaluations of human papillomavirus vaccines. Expert Rev Pharmacoeconomics Outcomes Res 2007; 7: 1–17CrossRef
23.
Marra F, Cloutier K, Oteng B, et al. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2008; 27 (2): 127–47CrossRef
24.
25.
Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769
26.
Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359: 821–32PubMedCrossRef
Metadata
Title
Controlling Cervical Cancer
Authors
Maurizio Bonati
Prof. Silvio Garattini
Publication date
01-02-2009
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 2/2009
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200927020-00001

Other articles of this Issue 2/2009

PharmacoEconomics 2/2009 Go to the issue

Original Research Article

Willingness to Pay for a Treatment for Pain in Multiple Sclerosis

Leading Article

Neuropathic Pain

Review Article

Economics of Treatments for Non-Small Cell Lung Cancer

Original Research Article

Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV

Original Research Article

Challenges in Merging Medicaid and Medicare Databases to Obtain Healthcare Costs for Dual-Eligible Beneficiaries

Review Article

Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine